对p90核糖体S6激酶的治疗向
Eric B Wright1, Deborah A Lannigan1,2
1Department Biomedical Engineering, Vanderbilt University, Nashville, TN, United States.
Frontiers in cell and developmental biology
|January 3, 2024
概括
p90核糖体S6激酶 (RSK) 对细胞功能和癌症至关重要,但开发特定的抑制剂具有挑战性. 对于有效的癌症治疗,需要异型特异的RSK抑制剂.
科学领域:
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
- 癌症治疗方法 癌症治疗方法
背景情况:
- p90核糖体S6激酶 (RSK) 是ERK1/2信号传导的关键下游效应因子,由受体氨酸激酶和GPCRs激活.
- RSK调节关键细胞过程,包括转录,增殖,生存和炎症,并负面调节ERK1/2信号传递.
- RSK与癌症有关,导致转变和转移,但特定的抑制剂落后于其他MAPK通路成员.
研究的目的:
- 审查RSK在细胞平衡和癌症中的作用.
- 讨论开发用于癌症治疗的RSK特异性抑制剂的挑战和潜在策略.
- 突出CTKD抑制剂的局限性和针对NTKD的向疗法的潜力.
主要方法:
- 关于RSK信号通路的文献综述.
- 在正常和癌细胞中分析RSK功能.
- 讨论针对RSK的当前和潜在的治疗策略.
主要成果:
- RSK包括两个激酶域 (NTKD和CTKD),其中NTKD介导基质酸化.
- RSK异型具有重叠的,但又不同的功能,根据组织类型而异.
- 一种泛RSK抑制剂 (PMD-026) 正在临床试验中,但可能需要异型特异性抑制剂.
结论:
- 开发特定于异形的RSK抑制剂对于有效的癌症治疗至关重要,因为异形的功能不同.
- CTKD 抑制剂具有有限的治疗效用,但可以帮助开发化向嵌合体.
- 针对非常相似的NTKD域为开发选择性RSK抑制剂带来了重大挑战.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K